Column
- HOME
- Column
You can view the research column published every month by SMC Laboratories.
2025.01.28
[New Data!] Etrasimod in IBD Mouse Models
We are excited to share new efficacy data for Etrasimod (VELSIPITY) in inflammatory bowel disease (IBD) mouse models. Etrasimod, a sphingosine 1-phosphate (S1P) receptor modulator, was approved on October 12, 2023, as an oral treatment for ulcerative colitis. Building on our previous efficacy data for Mesalazine and Tacrolimus in IBD models, we have now…
2024.04.08
【Hot data】 Resmetirom (MGL-3196) evaluation data available in STAMTM model
MASH Resmetirom STAM
As you may already know, the United States Food and Drug Administration (FDA) announced the approval of Rezdiffra (resmetirom), developed by Madrigal Pharmaceuticals, as the first treatment for MASH. If you are developing a MASH treatment in this situation, you have the possibility to utilize the STAM™-HCC/IO+ model and get the most out of…
2024.03.21
What is the best non-clinical liver cancer model with 100% cancer incidence rate and suitable for liver cancer assessment?
If you are considering a drug evaluation study for liver cancer using a mouse model, our STAMTM-HCC/IO+ model best replicates the pathology and characteristics seen in human patients with liver cancer, which allows for the optimal evaluation of your compound’s efficacy. In addition to molecular targeted drugs such as lenvatinib and sorafenib, immune checkpoint inhibitors…
2024.03.19
[ Breaking News! ] First MASH treatment approved by FDA
On March 14th, industry-altering news was published. Do you know already what we are talking about? The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (resmetirom), developed by Madrigal Pharmaceuticals, as the first treatment for MASH. FDA approved first MASH treatment We are truly excited that a drug has been approved…
2024.03.15
[Existing compounds] that have advanced to clinical trials will accelerate the launch of your drugs.
If you are planning to launch your therapeutic drug, you should select disease mouse models that have shown action and efficacy in the same pathway and have progressed to the clinical trial. The reason being that although there are many potential therapeutic targets for MASH/NASH, there are currently no approved drugs for the treatment of…
2024.03.15
Pitfalls of [ disease model mice ] that researchers unknowingly fall into.
In order to evaluate your compound, rather than using a general pulmonary fibrosis model that does not match your pathology, you should use one that allows you to successfully evaluate your desired pathologies. We have seen some cases where this has not been achieved. The bleomycin-induced pulmonary fibrosis model is commonly used to reproduce the…
2024.03.15
| A must for IPF researchers! | Suggestions for the best disease model for your research
If you are considering a drug efficacy study using a mouse model of lung fibrosis, you should use a model that best suits your purpose, rather than a generic study design for that model. The bleomycin-induced lung fibrosis model is widely used for drug efficacy studies, and the general study design for it is publicly…
We can help you advance your research.